095700.KQライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (3 5月 2024 @ 15:30):

Genexine, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of immunotherapeutics and long-acting biologics in South Korea...

Stats
本日の出来高	62 989.00
平均出来高	217 175
時価総額	318.33B
EPS	KRW0 ( 2024-02-08 )
次の収益日	( KRW229.00 ) 2024-05-12
Last Dividend	KRW0 ( N/A )
Next Dividend	KRW0 ( N/A )
P/E	0
ATR14	KRW12.30 (0.16%)

ボリューム相関

長: -0.10 (neutral)

短: 0.37 (neutral)

Signal:(55.461) Neutral

Genexine, Inc. 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Genexine, Inc. 相関 - 通貨/商品

0.45
( neutral )

0.17
( neutral )

-0.06
( neutral )

0.48
( neutral )

-0.11
( neutral )

Genexine, Inc. 財務諸表

Annual	2023
収益:	KRW4.43B
総利益:	KRW-4.00B (-90.32 %)
EPS:	KRW-1 652.14

FY	2023
収益:	KRW4.43B
総利益:	KRW-4.00B (-90.32 %)
EPS:	KRW-1 652.14

FY	2022
収益:	KRW16.14B
総利益:	KRW7.30B (45.26 %)
EPS:	KRW-1 326.23

Financial Reports:

No articles found.

Genexine, Inc.

Genexine, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of immunotherapeutics and long-acting biologics in South Korea. It develops hyFc platform, a proprietary technology designed to drive the discovery of various differentiated agonistic protein therapeutics; and the Immune Enhancing Technology, a therapeutic DNA vaccine technology. The company's product pipeline includes GX-H9, which is in Phase II clinical trials for the treatment of adult and pediatric growth hormone deficiency; GX-E2, which is in Phase II clinical trials for the treatment of induced anemia; GX-G3, which is in Phase II clinical trials to treat neutropenia; and GX-G6 that is in Phase I clinical trials for the treatment of diabetes. It is also developing GX-188E that is in Phase II clinical trials in combination with KEYTRUDA for the treatment of cervical cancer. Genexine, Inc. has a co-development partnership with Binex Co. Ltd. to develop COVID-19 vaccine. The company was formerly known as Genexine Co., Ltd. and changed its name to Genexine, Inc. in March 2013. Genexine, Inc. was founded in 1999 and is based in Seongnam, South Korea.